Molecular Partners Ag (MOLN) Enterprise Value (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Enterprise Value of -$100587.1 for Q1 2026, up 100.0% year-over-year from -$50293.6 in Q1 2025, and down 666.56% quarter-over-quarter from -$13121.8 in Q4 2025.
Molecular Partners Ag (MOLN) Enterprise Value (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Enterprise Value for 7 consecutive years, with -$100587.1 the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 100.0% year-over-year to -$100587.1; the TTM figure through Mar 2026 stood at -$100587.1 (up 100.0% YoY), while the FY2025 annual figure was -$13121.8, up 99.99% from the prior year.
- Enterprise Value eased to -$100587.1 in Q1 2026 per MOLN's latest filing, from -$13121.8 in the prior quarter.
- Across five years, Enterprise Value topped out at -$13121.8 in Q4 2025 and bottomed at -$153.8 billion in Q1 2022.
- Historically, Enterprise Value has averaged -$37.0 billion across 5 years, with a median of -$258.6 million in 2022.
- Annual changes were most pronounced in 2022 — Enterprise Value slumped 113.25% — and 2026, when it jumped 100.0%.
- Molecular Partners Ag's Enterprise Value stood at -$258.6 million in 2022, then gained by 18.53% to -$210.7 million in 2023, then rose by 19.03% to -$170.6 million in 2024, then surged by 99.99% to -$13121.8 in 2025, then plunged by 666.56% to -$100587.1 in 2026.
- Business Quant data shows MOLN's Enterprise Value at -$100587.1 in Q1 2026, -$13121.8 in Q4 2025, and -$130662.7 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Molecular Partners Ag | 163.25 Mn | 163.25 Mn | - | -100,587.10 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -100,587.10 |
| Dec 31, 2025 | -13,121.83 |
| Sep 30, 2025 | -130,662.70 |
| Jun 30, 2025 | -39,368.74 |
| Mar 31, 2025 | -90.50 Bn |
| Dec 31, 2024 | -170.59 Mn |
| Sep 30, 2024 | -75.89 Bn |
| Jun 30, 2024 | -174.17 Mn |
| Mar 31, 2024 | -78.30 Bn |
| Dec 31, 2023 | -210.69 Mn |
| Sep 30, 2023 | -77.44 Bn |
| Jun 30, 2023 | -242.67 Mn |
| Mar 31, 2023 | -79.93 Bn |
| Dec 31, 2022 | -258.62 Mn |
| Sep 30, 2022 | -72.17 Bn |
| Jun 30, 2022 | -295.98 Mn |
| Mar 31, 2022 | -153.78 Bn |
| Dec 31, 2021 | -144.04 Mn |
| Sep 30, 2021 | -90.29 Bn |
| Jun 30, 2021 | -138.80 Mn |